ReDS-guided decongestion for people hospitalized with heart failure
Official title: ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure: the ReDS-SAFE HF II Trial
Run by Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · NCT07484009 · Data updated 2026-11-12
This test will see if using a ReDS chest sensor to guide fluid removal helps adults hospitalized for heart failure have fewer heart-related problems in the month after discharge.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1014 (estimated) |
| Sponsor | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal Academic / other |
| Locations | 25 sites (Madrid, Madrid and 24 other locations) |
| Status | Recruiting |
| Started | January 29, 2026 |
| Main results expected | June 30, 2027 |
| Study ends | August 31, 2027 |
| Registry record updated | March 19, 2026 |
| Trial ID | NCT07484009 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults hospitalized primarily for heart failure with clinical signs of congestion and admission NT-proBNP >1000 pg/L or BNP >300 pg/L, and with height and BMI within the ReDS-approved ranges, are ideal candidates.
✕Probably not a fit
Patients who need inotropes or vasopressors, have mechanical circulatory support or planned cardiac surgery/intervention, have incompatible lung anatomy or height/BMI, severe kidney failure on dialysis, or life expectancy under 12 months are unlikely to benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized interventional study compares a ReDS-guided decongestion strategy to usual care in adults admitted for acute heart failure with signs of congestion and elevated natriuretic peptides. Participants will have daily ReDS measurements during hospitalization and will be randomized to treatment guided by those measurements or to standard care with ReDS data blinded. Investigators will track cardiovascular events in the first 30 days after discharge, and will monitor safety and costs of the approach. Two follow-up visits are scheduled at about 2 weeks and 30 days after discharge to capture outcomes and adverse events.
Why it matters
Potential benefit: If successful, the ReDS-guided approach could reduce early post-discharge heart-related events and help tailor diuretic therapy to decrease rehospitalizations and costs.
How similar studies have gone: Some prior studies have shown ReDS can detect lung fluid and guide outpatient management, but using ReDS-guided decongestion in hospitalized patients to reduce early post-discharge events is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Hospitalized due to heart failure as the main reason, including the presence of symptoms and signs of congestion, regardless of the left ventricular ejection fraction (LVEF). 2. NT-proBNP greater than 1000 pg/L or BNP greater than 300 pg/L upon admission. Exclusion Criteria: 1. Height less than 150 cm or greater than 190 cm or body mass index (BMI) less than 22 or greater than 39, conditions where the use of ReDS is not approved. 2. Patients requiring inotropes (levosimendan is allowed) or vasopressors upon admission, with mechanical support, or heart transplant recipients. 3. Any malformation or variant affecting the right lung anatomy (e.g., a pacemaker). 4. Patients with any heart disease requiring a planned surgical intervention (CABG, valve disease, or other) or percutaneous (TAVR, STE-ACS, mitral or tricuspid valve repair, CRT) during the clinical trial. 5. Chronic kidney disease with a GFR \<20 or on hemodialysis. 6. Life expectancy less than 12 months due to non-cardiological origin. 7. Participation in another clinical trial with intervention.
Where it's running
-
Ramón y Cajal University Hospital
Madrid, Madrid, Spain Recruiting -
Bellvitge University Hospital
Barcelona, Spain Recruiting -
Hospital del Mar
Barcelona, Spain Recruiting -
Reina Sofía University Hospital
Córdoba, Spain Recruiting -
Dr Josep Trueta University Hospital
Girona, Spain Recruiting -
12 de Octubre University Hospital
Madrid, Spain Recruiting
Show 19 more locations
-
La Paz University Hospital
Madrid, Spain Recruiting -
Puerta de Hierro Majadahonda University Hospital
Madrid, Spain Recruiting -
Virgen de la Victoria University Hospital
Málaga, Spain Recruiting -
San Juan Despí Moisès Broggi Hospital
Sant Joan Despí, Spain Recruiting -
Complejo Hospitalario Universitario de Santiago
Santiago de Compostela, Spain Recruiting -
Arnau de Vilanova University Hospital
Barcelona, Spain Not yet recruiting -
Hospital Clinic
Barcelona, Spain Not yet recruiting -
Vall d'Hebrón University Hospital
Barcelona, Spain Not yet recruiting -
Clínico San Carlos University Hospital
Madrid, Spain Not yet recruiting -
Fundación Jiménez Díaz University Hospital
Madrid, Spain Not yet recruiting -
Gregorio Marañón University Hospital
Madrid, Spain Not yet recruiting -
La Princesa University Hospital
Madrid, Spain Not yet recruiting -
Virgen de la Arrixaca
Murcia, Spain Not yet recruiting -
Complejo Asistencial Universitario de Salamanca
Salamanca, Spain Not yet recruiting -
Marqués de Valdecilla University Hospital
Santander, Spain Not yet recruiting -
Virgen de la Macarena University Hospital
Seville, Spain Not yet recruiting -
Sant Joan XXIII University Hospital
Tarragona, Spain Not yet recruiting -
Hospital General Universitario de Toledo
Toledo, Spain Not yet recruiting -
Clínico University Hospital
Valencia, Spain Not yet recruiting
Study contacts
- Principal investigator: Jesús Álvarez-García, MD, PhD — Ramón y Cajal University Hospital, Madrid, Spain
- Study coordinator: Jesús Álvarez-García, MD, PhD
- Email: jalvarezg82@gmail.com
- Phone: 34 667495661
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comprehensive clinical rule to diagnose acute heart failure in the emergency department
A prospective study tests a combined clinical rule using patient data, a point-of-care NT-proBNP test, an 8-point lung ultrasound, and bedside echo to quickly diagnose acute heart failure in adults with new or worsening symptoms.
-
Disrupted congestion in acute heart failure: can ultrasound at discharge predict readmission and death
This study tests whether ultrasound checks of congestion at discharge can predict which patients with acute heart failure are more likely to be readmitted or die within 90 days.
-
Non-Invasive Heart Failure Monitoring in Hospitalized Patients
This study tests whether daily non-invasive thoracic measurements from the Acorai Device 1.0 can relate to health outcomes for adults hospitalized with heart failure.
-
Pre-discharge Flu Vaccine for patients with acute heart problems
This trial tests whether giving an influenza vaccine within 24 hours before hospital discharge helps patients who were treated for acute heart issues stay healthier this season.
-
Acute Heart Failure: How a Quantitative ECG Helps Clinicians
This study tests whether quantitative ECG (QCG) measurements can reveal useful patterns in adults hospitalized with acute heart failure.
-
Urinary Sodium and Chloride Changes and Fluid Overload in Acute Heart Failure
This study tests whether tracking urinary sodium and chloride during hospitalization can reflect congestion removal and predict short-term outcomes in adults with acute heart failure treated with IV diuretics.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.